Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DOT1L | Q8TEK3 | 2/20 | 0.35 |
| ▸ | POLRMT | O00411 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9912317 | 1.00 | DOT1L (0.35) | DOT1LPOLRMTSMN1; SMN2USP2ALDH1A1 | |
| SCHEMBL13532238 | 0.88 | SMN1; SMN2 (0.33) | SMN1; SMN2 | |
| SCHEMBL18666890 | 0.84 | HSPA5 (0.36) | DOT1LPOLRMT | |
| SCHEMBL9912314 | 0.83 | PIK3CD (0.32) | SMN1; SMN2 | |
| SCHEMBL15605849 | 0.81 | DOT1L (0.34) | DOT1LPOLRMT | |
| SCHEMBL13696066 | 0.81 | DOT1L (0.37) | DOT1LPOLRMT | |
| SCHEMBL13532219 | 0.81 | DOT1L (0.37) | DOT1LPOLRMT | |
| SCHEMBL20058766 | 0.81 | DOT1L (0.37) | DOT1LPOLRMT | |
| SCHEMBL13532236 | 0.80 | ALDH1A1 (0.33) | SMN1; SMN2USP2ALDH1A1POLBALOX15 | |
| SCHEMBL10112577 | 0.80 | DOT1L (0.36) | DOT1LPOLRMTUSP2ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227524-A1 | ANTIVIRAL THERAPEUTIC AGENTS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227524-A1 | ANTIVIRAL THERAPEUTIC AGENTS | EIF2AK2, ZC3HAV1, MAVS | DOT1L 3413/4885POLRMT 32/4885SMN1; SMN2 2147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.